The expression of DNMT3b/OCT4 may confer sorafenib resistance in HCC, and the DNMT3b inhibitor exhibited a synergistic effect with sorafenib on sorafenib-resistant liver cancer. This evidence concerns the gene POU5F1 and hepatocellular carcinoma.